Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02670304
Recruitment Status : Completed
First Posted : February 1, 2016
Last Update Posted : February 1, 2016
Sponsor:
Information provided by (Responsible Party):
Zhou Canquan, First Affiliated Hospital, Sun Yat-Sen University

Brief Summary:
Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.

Condition or disease Intervention/treatment Phase
Ovarian Hyperstimulation Syndrome Drug: letrozole Drug: Aspirin Phase 4

Detailed Description:
Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment
Study Start Date : January 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: letrozole
letrozole for the first day after ovum picked up at least for 5 days.
Drug: letrozole
letrozole from the day of oocyte retrieval for 5 days
Other Name: Femara

Active Comparator: aspirin
asprin for the first day after ovum picked up at least for 5 days.
Drug: Aspirin
aspirin from the day of oocyte retrieval for 5 days




Primary Outcome Measures :
  1. incidence of early OHSS [ Time Frame: up to 1 months ]

Secondary Outcome Measures :
  1. vascular endothelial growth factor level [ Time Frame: up to 1 months ]
    vascular endothelial growth factor in pg/ml

  2. incidence of hydrothorax [ Time Frame: up to 1 months ]
  3. incidence of liver dysfunction [ Time Frame: up to 1 months ]
  4. incidence of renal dysfunction [ Time Frame: up to 1 months ]
  5. incidence of electrolytic imbalance [ Time Frame: up to 1 months ]
  6. incidence of hemoconcentration [ Time Frame: up to 1 months ]
  7. incidence of elevated WBC [ Time Frame: up to 1 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • infertile women undergoing IVF treatment with more than 25 oocytes collected.

Exclusion Criteria:

  • letrozole contraindications,e.g. severe hepatic and renal dysfunction
Layout table for additonal information
Responsible Party: Zhou Canquan, Principal Investigator, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT02670304    
Other Study ID Numbers: 28843020
First Posted: February 1, 2016    Key Record Dates
Last Update Posted: February 1, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no plan to make IPD available
Keywords provided by Zhou Canquan, First Affiliated Hospital, Sun Yat-Sen University:
letrozole
ovarian hyperstimulating syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Hyperstimulation Syndrome
Syndrome
Disease
Pathologic Processes
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Aspirin
Letrozole
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Estrogen Antagonists
Hormone Antagonists